{
    "name": "flortaucipir F 18",
    "comment": "Rx",
    "other_names": [
        "Tauvid"
    ],
    "classes": [
        "Diagnostic Imaging Agents"
    ],
    "source": "https://reference.medscape.com/drug/tauvid-flortaucipir-f-18-4000114",
    "pregnancy": {
        "common": [
            "All radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose",
            "Advise pregnant females of potential risks of fetal exposure to radiation",
            "Not likely to be used in females of reproductive age",
            "No data available use in pregnant females"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no data on the presence of flortaucipir F 18 in human milk, or its effects on breastfed infants or milk production",
            "Advise a lactating females to avoid breastfeeding for 4 hr after administration in order to minimize radiation exposure to a breastfed infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Safety and efficacy not established for patients being evaluated for CTE"
            ],
            "specific": [
                {
                    "type": "Risk for misdiagnosis",
                    "description": [
                        "Imaging agent does not target beta-amyloid, 1 of 2 required components of the neuropathological diagnosis of AD",
                        "Performance for detecting tau pathology was assessed in terminally ill patients, the majority of whom had AD dementia with B3 level NFT pathology",
                        "Performance for detecting tau pathology may be lower in patients in earlier stages of the pathological spectrum",
                        "Negative scan",
                        "NFTs may be present at levels that qualify for neuropathological diagnosis of AD (B2 tau pathology in presence of at least moderate levels of cortical amyloid pathology) ",
                        "Consider additional evaluation to confirm absence of AD pathology",
                        "False-positive scan",
                        "Small foci of noncontiguous tracer uptake may lead to a false-positive scan",
                        "Only uptake of tracer in neocortex should contribute to interpretation of a positive scan"
                    ]
                },
                {
                    "type": "Radiation risk",
                    "description": [
                        "Diagnostic radiopharmaceuticals expose patients to radiation",
                        "Radiation exposure is associated with a dose-dependent increased risk of cancer",
                        "Ensure safe handling and preparation procedures to protect patients and health-care workers from unintentional radiation exposure"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "1.4"
        },
        {
            "name": "Injection site pain",
            "percent": "1.2"
        },
        {
            "name": "Increased blood pressure",
            "percent": "0.8"
        }
    ]
}